{"title": "PDF", "author": "PDF", "url": "https://www.samfyc.es/wp-content/uploads/2018/08/AlertaDiciembre2014.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Diciembre 2014  \n \nSelecci\u00f3n realizada por Antonio Manteca Gonz\u00e1lez  \n \nANNALS OF INTERNAL MEDICINE  \n \nLeFevre ML; U.S. Preventive Services Task Force. Low -dose aspirin use for the prevention of morbidity and mortality \nfrom preeclampsia:  U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:819 -826 \n[M,III]  \n25200125  R/C \nUSO DE ASPIRINA EN DOSIS BAJA PARA LA PREVENCI\u00d3N DE  LA MORBILIDAD Y MORTALIDAD EN LA \nPREECLAMPSIA: DECLARACI\u00d3N DE RECOMENDACI\u00d3N DEL USPSTF  \n \nIsakov A, Jamison A, Miles W, Ribner B. Safe management of patients with serious communicable diseases: recent \nexperience with Ebola virus. Ann Intern Med 2014;161:829 -830 [AO,I]  \n25244492   \nMANEJO SEGURO DE LOS PACIENTES CON ENFERMEDADES TRANSMISIBLES GRAVES: EXPE RIENCIA \nRECIENTE CON EL VIRUS DE L \u00c9BOLA  \n \nZakher B, Cantor AG, Pappas M, Daeges M, Nelson HD. Screeni ng for gonorrhea and Chlamydia: a systematic review \nfor the U.S. Preventive Services Task Force. Ann Intern Med 2014;161:884 -893 [M,II]  \n25244000  R/C \nCRIBAJE DE GONORRE A Y CLAMIDIA: REVISI\u00d3N SISTEM\u00c1TICA PARA EL USPSTF  \n \nLeFevre ML; U.S. Preventive Services Task Force. Behavioral counseling interventions to prevent sexually transmitted \ninfections: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med  2014;161:894 -901 [M,II]  \n25244227  R/C \nINTERVENCIONES DE CONSEJO CONDUCTUAL PARA PREVENIR LAS INFECCIONES DE TRANSMISI\u00d3N \nSEXUAL: DECLARACI\u00d3N DE RECOMENDACI\u00d3N DEL USPSTF  \n \nLeFevre ML; U.S. Preventive Services Task Force. Screening for Chlamydia and gonorrhea: U.S. Preventive Services \nTask Force recommendation statement. Ann Intern Med 2014;161:902 -910 [M,II]  \n252437 85 R/C \nCRIBAJE DE GONORREA Y CLAMIDIA: DECLARACI\u00d3N DE RECOMENDACI\u00d3N DEL USPSTF  \n \nARCHIVOS DE BRONCONEUMOLOGIA  \n \nLopez -Campos JL, Lopez -Ramirez C, Marquez -Mart\u00edn E. Agudizaciones de la enferme dad pulmonar obstructiva cr\u00f3nica \ny condensaci\u00f3n radiol\u00f3gica: tres preguntas controvertidas. Arch Bronconeumol 2014;50:503 -504 [AO,I]  \n25457938  \nAGUDIZACIONES DE LA ENFERMEDAD PULMONAR OBSTRUCTIVA CR \u00d3NICA Y CONDENSACI\u00d3N \nRADIOL\u00d3GICA: TRES PREGUNTAS CONTROVERTIDAS  \n \nBoixeda R, Bacca S, Elias L, Capdevila JA, Vil\u00e0 X, Mauri M, et al. La neumon\u00eda como comorbilidad en la enfermedad \npulmonar obstructiva cr\u00f3nica (EPOC). Arch Bronconeumol 2014;50:514 -520 [S,I]  \n25443591  R/C \nLA NEUMON\u00cdA COMO COMORBILIDAD EN LA ENFERMEDAD PULMONAR OBSTRUCTIVA CR\u00d3NICA (EPOC)  \n \nGonz\u00e1lez N, Troncoso MF, G\u00f3mez T. Terapias ventilatorias domiciliarias  en el s\u00edndrome de apnea -hipopnea del sue\u00f1o. \nArch Bronconeumol 2014;50:528 -534 [R,I]  \n25059585  R/C \nTERAPIAS VENTILATORIAS DOMICILIARIAS EN EL S\u00cdNDROME DE APNEA -HIPOPNEA  DEL SUE\u00d1O  \n \nARTHRITIS AND RHEUMATOLOGY  \n \nYoo JJ, Cho NH, Lim SH, Kim HA. Relationships between body mass index, fat mass, muscle mass, and \nmusculoskeletal pain in community residents. Arthritis Rheumatol 2014;66:3511 -3520 [T,I]  \n25185757  R/C \nRELACIONES ENTRE IMC, MASA GRASA, MASA MUSCULAR Y DOLOR OSTEOMUSCULAR EN RESIDENTES EN \nLA COMUNIDAD  \n \nATENCION PRIMARIA  \n \nMora RM. Concilia ci\u00f3n y prescripci\u00f3n electr\u00f3nica. Aten Primaria 2014;46:529 -530 [AO,I]  \n25458923  \nCONCILIACI\u00d3N Y PRESCRIPCI\u00d3N ELECTR\u00d3NICA  \n \nL\u00f3pez -Torres J, Basora J, Orozco D, Bell\u00f3n J\u00c1. Mapa bibliom\u00e9trico de la inve stigaci\u00f3n realizada en atenci\u00f3n primaria en \nEspa\u00f1a durante el periodo 2008 -2012. Aten Primaria 2014;46:541 -548 [T,I]  24811538  R/C \nMAPA BIBLIOM\u00c9TRICO DE LA INVESTIGACI\u00d3 N REALIZADA EN ATENCI\u00d3N PRIMARIA EN ESPA\u00d1A DURANTE EL \nPERIODO 2008 -2012  \n \nGancedo -Garc\u00eda A, Guti\u00e9rrez -Antezana AF, Gonz\u00e1lez -Garc\u00eda P, Salinas -Herrero S, Prieto -Merino D, Su\u00e1rez -Gil P. \nEfectividad de una intervenci\u00f3n educativa breve en pacientes con insomnio  en atenci\u00f3n primaria. Aten Primaria \n2014;46:549 -557 [EC,I]  \n24986634  R/C \nEFECTIVIDAD DE UNA INTERVENCI\u00d3N EDUCATIVA BREVE EN PACIENTES CON INSOMNIO EN ATENCI\u00d3N \nPRIMARIA  \n \nMaestre -Miquel C, Mart\u00ednez D, Polonio B, Astasio P, Santos J, Regidor E. Desigualdades en inactividad f\u00edsica seg\u00fan el \nnivel de estudios en Espa\u00f1a, en 1987 y 2007. Aten Primaria 2014;46:565 -572 [T,I]  \n24863857  R/C \nDESIGUALDADES EN INACTIVIDAD F\u00cdSICA SEG\u00daN EL NIVEL DE ESTUDIOS EN ESPA\u00d1A, EN 1987 Y 2007  \n \nCatal\u00e1 -L\u00f3pez F, Tob\u00edas A, Roqu\u00e9 M. Conceptos b\u00e1sicos del metaan\u00e1lisis en red. Aten Primaria 2014;46:573 -581 [R,I]  \n  R/C \nCONCEPTOS B\u00c1SICOS DEL METAAN\u00c1LISIS EN RED  \n \nBRITISH JOURNAL OF PSYCHIATRY  \n \nSavic C, Belkic K. Why are job stressors relevant for psychiatry? Br J Psychiatry 2014;205:425 -427 [AO,I]  \n25452599  R/C \n\u00bfPOR QU\u00c9 SON RELEVANTES EN PSIQUIATR\u00cdA LOS ESTRESORES LABORALES?  \n \nLivingston G, Kelly L, Lewis -Holmes E, Baio G, Morris S, Patel N, et al. Non -pharmacological interventions f or agitation \nin dementia: systematic review of randomised controlled trials. Br J Psychiatry 2014;205:436 -442 [M,II]  \n25452601  R/C \nINTERVENCIONES NO FARMACOL\u00d3GICAS PARA  LA AGITACI\u00d3N EN LA DEMENCIA: REVISI\u00d3N SISTEM\u00c1TICA DE \nENSAYOS CONTROLADOS ALEATORIZADOS  \n \nFountoulakis KN, Kawohl W, Theodorakis PN, Kerkhof AJ, Navickas A, H\u00f6schl C, et al. Relationship of suicide rates to \neconomic variables in Europe: 2000 -2011. Br J Psyc hiatry 2014;205:486 -496 [T,II]  \n25359926  R/C \nRELACI\u00d3N DE TASAS DE SUICIDIO CON VARIABLES ECON\u00d3MICAS EN EUROPA: 2000 -2011  \n \nBRITISH MEDICAL JOURNAL  \n \nWood LN, Anger JT. Urinary incontinence in women. BMJ 2014;349:g4531 [R,I]  \n25225003  R/C \nINCONTINENCIA URINARIA EN MUJERES  \n \nNeal RD, Hamilton W, Rogers TK. Lung canc er. BMJ 2014;349:g6560  \n[R,I] \n25376443  \nC\u00c1NCER DE PULM\u00d3N  \n \nYang JH, Hahn JY, Song YB, Choi SH, Choi JH, Lee SH, et al. Angiotensin receptor blocker in patients with ST segment \nelevation myocardial i nfarction with preserved left ventricular systolic function: prospective cohort study. BMJ \n2014;349:g6650 [S,I]  \n25398372  R/C \nBLOQUEANTES DEL RECEPTOR DE ANGIOTENSINA E N PACIENTES CON INFARTO DE MIOCARDIO CON \nELEVACI\u00d3N DEL SEGMENTO ST CON FUNCI\u00d3N SIST\u00d3LICA VENTRICULAR PRESERVADA: ESTUDIO DE \nCOHORTE PROSPECTIVO  \n \nEccles S, Pincus C, Higgins B, Woodhead M; Guideline Development Group. Diagnosis and management of community \nand hospital acquired pneumonia in adults: summary of NICE guidance. BMJ 2014;349:g6722  \n[M,II]  \n25471702   \nDIAGN\u00d3STICO Y TRATAMIENTO DE NEUMON\u00cdA ADQUIRIDA EN LA COMUNIDAD Y ADQUIRIDA EN EL HOSPITAL \nEN ADULTOS: RESUMEN DE LA GU\u00cdA NICE  \n \nHole B, Whittlestone T, Tomson C. Investigating asymptomatic invisible haematuria. BMJ 2014;349:g6768  \n[R,I] \n25404006   \nINVESTIGAR LA HEMATURIA OCULTA ASINTOM\u00c1T ICA \n \nSumner P, Vivian -Griffiths S, Boivin J, Williams A, Venetis CA, Davies A, et al. The association between exaggeration in \nhealth related science news and academic press releases: retrospective observational study. BMJ 2014;349:g7015 [T,I]  25498121  R/C \nASOCIACI\u00d3N ENTRE EXAGERACI\u00d3N EN LAS NOTICIAS CIENT\u00cdFICAS RELACIONADAS CON LA SALUD Y LOS \nCOMUNICADOS DE PRENSA ACAD\u00c9MICOS  \n \nChew M, Brizzell C, Abbasi K, Godlee F. Medi cal journals and industry ties. BMJ 2014;349:g7197 [AO,I]  \n25432164   \nREVISTAS M\u00c9DICAS Y LAZOS CON LA INDUSTRIA  \n \nNeville R, Austin S. The King Canute GP appointment system. BMJ 2014;349:g7228 [QE,I]  \n25500115   \nSISTEMA DE CITAS DE MEDICINA GENERAL DEL REY CANUTO  \n \nBrunet M. Target diagnosis rates in primary care are misleading and unethical. BMJ 2014;349:g7235  \n[R,I] \n25467381   \nLOS OBJETIVOS DE TASAS DIAGN\u00d3STICAS EN ATENCI\u00d3N PRIMARIA SON ENGA\u00d1OSOS Y POCO \u00c9TICOS  \n \nMeerman R, Brown AJ. When somebody loses weight, where does the fat go? BMJ 2014;349:g7257 [T,I]  \n25516540  \nCUANDO ALGUIEN PIERDE PESO \u00bfA D\u00d3NDE VA LA GRASA?  \n \nArroll B, Alrutz S, Moyes S. An exploration of the basis for patient complaints about the oldness of magazines in practice \nwaiting rooms: cohort study. BMJ 2014;349:g7 262 [S,I]  \n25500116  R/C \nEXPLORACI\u00d3N DE LA BASE DE LAS QUEJAS DE LOS PACIENTES SOBRE LA ANTIG\u00dcEDAD DE LAS REVISTAS \nEN LAS SALAS DE ESPERA DE LAS CONSULTAS: ESTUDIO DE CO HORTE  \n \nPage VJ. Delirium on the intensive care unit. BMJ 2014;349:g7265 [AO,I]  \nS\u00cdNDROME CONFUSIONAL EN LA UNIDAD DE CUIDADOS INTENSIVOS  \n \nBeeching NJ, Fenech M, Houlihan CF. Ebola virus disease. BMJ 2014;349:g7348  \n[R,II]  \n25497512  \nENFERMEDAD POR EL VIRUS DEL \u00c9BOLA  \n \nKoeck C. Imbalance of power between patients and doctors. BMJ 2014;349:g7485 [AO,I]  \n25512331   \nDESEQUILIBRIO DE PODER ENTRE PACI ENTES Y M\u00c9DICOS  \n \nSingleton N, Strang J. What would an evidence based drug policy be like? BMJ 2014;349:g7493 [AO,I]  \n25492041  \n\u00bfC\u00d3MO DEBER\u00cdA SER UNA POL\u00cdTICA FARMACOL\u00d3GICA BASADA EN LA EVIDENCIA?  \n \nWilkinson R, Pickett K. How 21st century capitalism is failing us. BMJ 2014; 349:g7516 [AO,I]  \n25512393   \nC\u00d3MO NOS EST\u00c1 DEFRAUDANOD EL CAPITALISMO EN EL SIGLO 21  \n \nCANADIAN MED ICAL ASSOCIATION JOURNAL  \n \nPoonai N, Bhullar G, Lin K, Papini A, Mainprize D, Howard J, et al. Oral administration of morphine versus ibuprofen to \nmanage postfracture pain in children: a randomized trial. CMAJ 2014;186:1358 -1363 [EC,I]  \n25349008  R/C \nADMINISTRACI\u00d3N ORAL DE MORFINA FRENTE A IBUPROFENO PARA TRATAR EL DOLOR POSTFRACTURA EN \nNI\u00d1OS: ENSAYO ALEATORIZADO  \n \nFrank C, Weir E. Deprescribing for older patients. CMAJ 20 14;186:1369 -1376 [AO,II]  \n25183716  \nDEPRESCRIBIR EN ANCIANOS  \n \nPonka D, Dickinson J. Screening with the Pap test. CMAJ 2014;186:1394 [AO,I]  \n25384655  \nCRIBAJE CON LA PRUEBA DE PAPANICOLAU  \n \nPadwal RS, Rabkin S, Khan N. Assessment and management of resistant hypertension. CMAJ 2014;186:E689 -E697 \n[R,I] \n25135921  \nVALORACI\u00d3N Y MANEJO DE LA H IPERTENSI\u00d3N RESISTENTE  \n \nCIRCULATION  \n January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the \nmanagement of patients with atrial fibrillation: executive summary: a re port of the American College of \nCardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation \n2014;130:2071 -2104 [M,III]  \n24682348  \nGU\u00cdA AHA/ACC/H RS 2014 PARA EL MANEJO DE PACIENTES CON FIBRILACI\u00d3N AURICULAR: RESUMEN \nEJECUTIVO: INFORME DEL ACC/GRUPO DE TRABAJO SOBRE GU\u00cdAS DE PR\u00c1CTICA CL\u00cdNICA DE LA AHA/HRS  \n \nJanuary CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/H RS guideline for the \nmanagement of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association \nTask Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;130:e199 -e267 [M,III]  \n24682347  \nGU\u00cdA AHA/ACC/HRS 2014 PARA EL MANEJO DE PACIENTES CON FIBRILACI\u00d3N AURICULAR: INFORME DEL \nACC/GRUPO DE TRABAJO SOBRE GU\u00cdAS DE PR\u00c1CTICA CL\u00cdNICA DE LA AHA/HRS  \n \nZhao W, Katzmarzyk PT, Horswell R, Wang  Y, Li W, Johnson J, et al. Body mass index and the risk of all -cause mortality \namong patients with type 2 diabetes. Circulation 2014 [Epub ahead of print]  \n[S,II] \n25378546  R/C \nIMC Y RIESGO DE MORTALIDAD POR CUALQUIER CAUSA ENTRE PACIENTES CON DIABETES TIPO 2  \n \nCarnethon MR. Diabetes in the absence of obesity: a risky condition. Circulation 2014 [Epub ahead of print]  \n[AO,I]  \n25378545  R/C \nDIABETES EN AUSENCIA DE OBESIDAD: ESTADO DE RIESGO  \n \nDIABETES CARE  \n \nCefalu WT, Petersen MP, Ratner RE. The alarming and rising costs of diabetes and prediabetes: a call for a ction! \nDiabetes Care 2014;37:3137 -3138 [AO,I]  \n25414386  \nLOS COSTES EN ASCENSO Y ALARMANTES DE LA DIABETES Y LA PREDIABETES: \u00a1LLAMAMIENTO  A LA \nACCI\u00d3N!  \n \nSpijkerman AM, van der A DL, Nilsson PM, Arda naz E, Gavrila D, Agudo A, et al; InterAct Consortium. Smoking and \nlong-term risk of type 2 diabetes: the EPIC -InterAct study in European populations. Diabetes Care 2014;37:3164 -3171 \n[S,II] \n2533674 9 R/C \nTABAQUISMO Y RIESGO DE DIABETES TIPO 2 A LARGO PLAZO : ESTUDIO EPIC -INTERACT EN POBLACIONES \nEUROPEAS  \n \nDall TM, Yang W, Halder P, Pang B, Massoudi M, Wintfeld N, et al. The economic burden of elevated blood glucose \nlevels  in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes Care \n2014;37:3172 -3179 [T,II]  \n25414388  R/C \nLA CARGA ECON\u00d3MICA DE  LOS NIVELES ELEVADOS DE AZ\u00daCAR EN SANGRE EN 2012: DIABETES \nDIAGNOSTICADA Y SIN DIAGNOSTICAR, DIABETES MELLITUS GESTACIONAL Y PREDIABETES  \n \nYki-J\u00e4rvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen -Bartmer I, Boelle E, et al; EDITION 2 Study \nInvestigators . New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral \nagents and basal insulin: glucose control and hypoglycemia in a 6 -month randomized controlled trial (EDITION 2). \nDiabetes Care 2014;37:3235 -3243 [EC, II] \n25193531  R/C \nNUEVA INSULINA GLARGINA 300 UU/ML FRENTE A LA GLARGINA 100 UU/ML EN PERSONAS CON DIABETES \nTIPO 2 QUE USAN AGENTES ORALES E INSULINA BASAL: CONTROL DE GLUCOSA E JHIPOGLUCEMIA EN UN \nENSAYO CONTROLADO ALEATORIZADO (EDITION 2)  \n \nRetnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic \u00df -cell \nfunction in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014 ;37:3270 -3278 [EC,I]  \n25249651  R/C \nLIRAGLUTIDA Y  PRESERVACI\u00d3N DE LA FUNCI\u00d3N DE LA C\u00c9LULA BETA PANCRE\u00c1TICA EN LA DIABETES TIPO 2 \nTEMPRANA: ENSAYO LIBRA  \n \nGarvey WT, Ryan  DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, et al. Weight -loss therapy in type 2 diabetes: \neffects of phentermine and topiramate extended release. Diabetes Care 2014;37:3309 -3316 [EC,I]  \n2524 9652  R/C \nTRATAMIENTO DE P\u00c9RDIDA DE PESO EN LA DIABETES TIPO 2: EFECTOS DE LA FENTERMINA Y EL \nTOPIRAMATO DE LIBERACI\u00d3N PROLONGADA  \n Viana LV, Gross JL, Azevedo MJ. Dietary intervention in patients with gestational diabetes melli tus: a systematic review \nand meta -analysis of randomized clinical trials on maternal and newborn outcomes. Diabetes Care 2014;37:3345 -3355 \n[M,II]  \n25414390  R/C \nINTERVEN CI\u00d3N DIET\u00c9TICA EN PACIENTES CON DIABETES MELLITUS GESTACIONAL: REVISI\u00d3N SISTEM\u00c1TICA \nY METAAN\u00c1LISIS DE ENSAYOS CL\u00cdNICOS ALEATORIZADOS SOBRE LOS RESULTADOS MATERNOS Y DE LOS \nRECI\u00c9N NACIDOS  \n \nDRUGS  \n \nLuke JJ, Ott PA, Shapiro GI. The bi ology and clinical development of MEK inhibitors for cancer. Drugs 2014;74:2111 -\n2128 [R,I]  \n25414119  R/C \nBIOLOG\u00cdA Y DESARROLLO CL\u00cdNICO DE LOS INHIBIDORES MEK PARA EL C\u00c1 NCER  \n \nCarris NW, Taylor JR, Gums JG. Combining a GLP -1 receptor agonist and basal insulin: study evidence and practical \nconsiderations. Drugs 2014;74:2141 -2152. [R,I]  \n25414121  R/C \nCOMBINAR AGONISTAS DE LOS RECEPTORES GLP -1 E INSULINA BASAL: EVIDENCIA DE LOS ESTUDIOS Y \nCONSIDERACIONES PR\u00c1CTICAS  \n \nScott LJ. Rifaximin: a review of its use in reducing recurrence of overt hepatic encephalopathy episodes. Drugs \n2014;74:2153 -2160 [R,I]  \n25352391  R/C \nRIFAXIMINA: REVISI\u00d3N DE SU USO PARA REDUCIR LAS RECURRENCIAS DE LOS EPISODIOS DE \nENCEFALOPAT\u00cdA HEP\u00c1TICA MANIFIESTA  \n \nScott LJ. Liraglutide: a revi ew of its use in adult patients with type 2 diabetes mellitus. Drugs 2014;74:2161 -2174 [R,I]  \n25367717  R/C \nLIRAGLUTIDA: REVISI\u00d3N DE SU USO EN PACIENTES ADULTOS CON DIAB ETES MELLITUS TIPO 2  \n \nFrampton JE. Pramipexole extended -release: a review of its use in patients with Parkinson's disease. Drugs \n2014;74:2175 -2190 [R,I]  \n25385556  R/C \nPRAMIPEXOL DE LIBERACI\u00d3N PROLONGADA: REVISI\u00d3N DE SU USO EN PACIENTES CON ENFERMEDAD DE \nPARKINSON  \n \nPlosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs 2014;74:2191 -2209 [R,I]  \n25389049  R/C \nDAPAGLIFLOZINA: REVISI\u00d3N DE SU USO EN PACIENTES CON DIABETES TIPO 2  \n \nENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA  \n \nGarc\u00eda -San Miguel L, Cobo J, Mart\u00ednez JA, A rnau JM, Murillas J, Pe\u00f1a C, et al; el Grupo REIPI. La \u00abintervenci\u00f3n del \ntercer d\u00eda\u00bb: an\u00e1lisis de los factores asociados al seguimiento de recomendaciones sobre la prescripci\u00f3n de antibi\u00f3ticos. \nEnferm Infecc Microbiol Clin 2014;32:654 -661 [EC,II]  \n24813928  R/C \nLA \u00abINTERVENCI\u00d3N DEL TERCER D\u00cdA\u00bb: AN\u00c1LISIS DE LOS FACTORES ASOCIADOS AL SEGUIMIENTO DE \nRECOMENDACIONES SOBRE LA PRESCRIPCI\u00d3N DE ANTIBI\u00d3TICOS  \n \nHern\u00e1ndez -Navarrete M J, Celorrio -Pascual JM, Lapresta C, Solano VM. Fundamentos de antisepsia, desinfecci\u00f3n y \nesterilizaci\u00f3n. Enferm Infecc Microbiol Clin 2014;32:681 -688 [R,II]  \n25023372  R/C \nFUNDAMENTOS DE ANTISEPSIA, DESINFECCI\u00d3N Y ESTERILIZACI\u00d3N  \n \nEUROPEAN HEART JOURNAL  \n \nKolandaivelu K, Leiden BB, O'Gara PT, Bhatt DL. Non -adherence to cardiovascular medications. Eur Heart J \n2014;35:3267 -3276 [R,I]  \n25265973  R/C \nFALTA DE CUMPLIMIENTO DE LA MEDICACI\u00d3N CARDIOVASCULAR  \n \nBanegas JR, Ruilope LM, de la Sierra A, de la Cruz JJ, Gorostidi M, Segura J, et al. High prevalence of masked \nuncontrolled hypertension in people with treated hypertension. Eur Heart J 2014;35:3304 -3312 [T,II]  \n24497346  R/C \nALTA PREVALENCIA OCULTA DE LA HIPERTENSI\u00d3N SIN CONTROL AR EN PERSONAS CON HIPERTENSI\u00d3N \nTRATADA  \n \nFAMILY PRACTICE   \nBurton C. Can we explain medically unexplained symptoms? Fam Pract 2014;31:623 -624 [AO,I]  \n25415972  \n\u00bfPODEMOS EXPLICA R LOS S\u00cdNTOMAS NO EXPLICADOS?  \n \nHaastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarb\u00f8l DE. Strategies for discontinuation of proton pump inhibitors: a \nsystematic review. Fam Pract 2014;31:625 -630 [M,II]  \n25192903  R/C \nESTRATEGIAS DE RETIRADA DE LOS INHIBIDORES DE LA BOMBA DE PROTONES: REVISI\u00d3N SISTEM\u00c1TICA  \n \nGlass GE, Tzafetta K. Bell's palsy: a summary of current evidence and referral algorithm. Fam Pract 2014;31:631 -642 \n[R,I] \n25208543  R/C \nPAR\u00c1LISIS DE BELL: RESUMEN DE LA EVIDENCIA ACTUAL Y ALGORITMO DE DERIVACI\u00d3N  \n \nBooth HP, Prevost TA, Wright AJ, Gulliford MC. Effectiveness of behavioura l weight loss interventions delivered in a \nprimary care setting: a systematic review and meta -analysis. Fam Pract 2014;31:643 -653 [M,II]  \n25298510  R/C \nEFECTIVIDAD DE LA S INTERVENCIONES CONDUCTUALES PARA LA P\u00c9RDIDA DE PESO EN UN DISPOSITIVO \nDE ATENCI\u00d3N PRIMARIA: REVISI\u00d3N SISTEM\u00c1TICA Y METAAN\u00c1LISIS  \n \nDoos L, Roberts EO, Corp N, Kadam UT. Multi -drug therapy in chronic condition multimorbidity: a systematic review. \nFam Pract 2014;31:654 -663 [M,II]  \n25192902  R/C \nTRATAMIENTO PLURIFARMACOL\u00d3GICO EN EL ESTADO DE PLURIMORBILIDAD CR\u00d3NICA: REVISI\u00d3N \nSISTEM\u00c1TICA  \n \nClarey J, Lasserson D, Levi C, Parson s M, Dewey H, Barber PA, et al. Absolute cardiovascular risk and GP decision \nmaking in TIA and minor stroke. Fam Pract 2014;31:664 -669 [S,II]  \n25208544  R/C \nRIESGO CARDI OVASCULAR ABSOLUTO Y TOMA DE DECISIONES DEL M\u00c9DICO GENERAL EN EL AIT Y EL \nICTUS MENOR  \n \nSchieber AC, Delpierre C, Lepage B, Afrite A, Pascal J, Cases C, et al; INTERMEDE group.  Do gender differences affect \nthe doctor -patient interaction during consultations  in general practice? Results from the INTERMEDE study. Fam Pract \n2014;31:706 -713 [T,II]  \n25214508  R/C \n\u00bfAFECTAN LAS DIFERENCIAS DE SEXO A LA INTERACCI\u00d3N M\u00c9DICO -PACIENTE  DURANTE LAS CONSULTAS \nDE MEDICINA GENERAL? RESULTADOS DEL ESTUDIO INTERMEDE  \n \nDarlow B, Dean S, Perry M, Mathieson F, Baxter GD, Dowell A. Acute low back pain management in general practice: \nuncertainty and conflicting certainties. Fam Pract 2014;31:723 -732 [C,I]  \n25192904  R/C \nMANEJO DEL DOLOR LUMBAR AGUDO EN MEDICINA GENERAL: INCERTIDUMBRE Y CERTEZAS CONFLICTIVAS  \n \nGACETA SANITARIA  \n \nL\u00f3pez -Cepero J, Lana A, Rodr\u00edguez -Franco L, Pa\u00edno SG, Rodr\u00edguez -D\u00edaz FJ. Percepci\u00f3n y etiquetado de la experiencia \nviolenta en las relaciones de noviazgo juvenil. Gac Sanit 2015;29:21 -26 [T,I]  \n25176129  R/C \nPERCEPCI\u00d3N Y ETIQUETADO DE LA EXPERIENCIA VIOLENTA EN LAS RELACIONES DE NOVIAZGO JUVENIL  \n \nAguilar -Palacio I, Carrera -Lasfuentes P, Rabanaque MJ. Salud percibida y nivel educativo en Espa\u00f1a: tendencias por \ncomunidades aut\u00f3nomas  y sexo (2001 -2012) Gac Sanit 2015;29:37 -43 [T,I]  \n25127554  R/C \nSALUD PERCIBIDA Y NIVEL EDUCATIVO EN ESPA\u00d1A: TENDENCIAS POR COMUNIDADES AUT\u00d3NOMAS Y SEXO \n(2001 -2012)  \n \nL\u00f3pez-Torres J, Rabanales J, Fern\u00e1ndez R, L\u00f3pez FJ, Panad\u00e9s L, Romero V. Resultados de un programa de \ntelemedicina para pacientes con diabetes tipo 2 en atenci\u00f3n primaria. Gac Sanit 2015;29:55 -58 [QE,I]  \n25440441  R/C \nRESULTADOS DE UN PROGRAMA DE TELEMEDICINA PARA PACIENTES CON DIABETES TIPO 2 EN ATENCI\u00d3N \nPRIMARIA  \n \nJOURNAL OF THE AMERICAN MEDICAL ASSOCIATION  \n \nSaini SD, van Hees F, Vijan S. Smarter s creening for cancer: possibilities and challenges of personalization. JAMA \n2014;312:2211 -2212 [AO,I]  \n25461993   \nUN CRIBAJE M\u00c1S INTELIGENTE DEL C\u00c1NCER: POSIBILIDADES Y RETOS DE LA PERSONALIZACI\u00d3N   \nGibbons RJ. Optimal medical therapy vs CT angiography screening for patients with diabetes. JAMA 2014;312:2219 -\n2220 [AO,I]  \n25402605   \nTRATAMIENTO M\u00c9DICO \u00d3PTIMO FRENTE A CRIBAJE ANGIOGR\u00c1FICO POR TC E N PACIENTES CON DIABETES  \n \nMuhlestein JB, Lapp\u00e9 DL, Lima JA, Rosen BD, May HT, Knight S, et al. Effect of screening for coronary artery disease \nusing CT angiography on mortality and cardiac events in high -risk patients with diabetes: the FACTOR -64 randomize d \nclinical trial. JAMA 2014;312:2234 -2243 [EC,II]  \n25402757  R/C \nEFECTO DEL CRIBAJE DE ENFERMEDAD ARTERIAL CORONARIA MEDIANTE ANGIOGRAF\u00cdA POR TC SOBRE LA \nMORTALIDAD Y LO S ACONTECIMIENTOS CARDIOVASCULARES EN PACIENTES DE ALTO RIESGO CON \nDIABETES: ENSAYO CL\u00cdNICO ALEATORIZADO FACTOR -64 \n \nNabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA 2014;312:2265 -2276 [M,II]  \n25461996  R/C \nLEUCEMIA LINFOC\u00cdTICA CR\u00d3NICA: REVISI\u00d3N  \n \nVolerman A, Cifu AS. Cervical cancer screening. JAMA 2014;312:2279 -2280 [AO,I]  \n25461998  \nCRIBAJ E DE C\u00c1NCER DE C\u00c9RVIX  \n \nEdmond MB, Diekema DJ, Perencevich EN. Ebola virus disease and the need for new personal protective equipment. \nJAMA 2014;312:2495 -2496 [AO,I]  \n25350321   \nENFERMEDAD POR VIRUS DEL \u00c9BOLA Y NECESIDAD DE NUEVOS EQUIPOS DE PROTECCI\u00d3N INDIVIDUAL  \n \nGaziano JM, Greenland P. When should aspirin be used for prevention of cardiovascular events? JAMA 2014;312:2503 -\n2504 [AO,I]  \n254026 71 \n\u00bfCU\u00c1NDO SE DEBER\u00cdA USAR LA ASPIRINA EN LA PREVENCI\u00d3N DE ACONTECIMIENTOS \nCARDIOVASCULARES?  \n \nEckel RH. Role of glycemic index in the context of an overall heart -healthy diet. JAMA 2014;312:2508 -2509 [AO,I]  \n25514301   \nPAPEL DEL \u00cdNDICE GLUC\u00c9MICO EN EL CONTEXTO DE UNA DIETA CARDIOSALUDABLE GLOBAL  \n \nIkeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low -dose aspirin for primary prevention of \ncardiovascular events in Japanese patie nts 60 years or older with atherosclerotic risk factors: a randomized clinical trial. \nJAMA 2014;312:2510 -2520 [EC,II]  \n25401325  R/C \nASPIRINA A DOSIS BAJA EN LA PREVENCI \u00d3N PRIMARIA DE ACONTECIMIENTOS CARDIOVASCULARES EN \nPACIENTES JAPONESES DE 60 A\u00d1OS O M\u00c1S CON FACTORES DE RIESGO ATEROSCLER\u00d3TICOS: ENSAYO \nCL\u00cdNICO ALEATORIZADO  \n \nSacks FM, Carey VJ, Anderson CA, Miller ER 3rd, Copeland T, Charleston J, et al. Effects of high v s low glycemic index \nof dietary carbohydrate on cardiovascular disease risk factors and insulin sensitivity: the OmniCarb randomized clinical \ntrial. JAMA 2014;312:2531 -2541 [EC,II]  \n25514303  R/C \nEFECTOS DE \u00cdNDICES GLUC\u00c9MICOS ALTOS FRENTE A BAJOS DE CARBOHIDRATOS EN LA DIETA SOBRE LOS \nFACTORES DE RIESGO DE ENFERMEDAD CARDIOVASCULAR Y LA SENSIBILIDAD A LA INSULINA: ENSAYO \nCL\u00cdNICO ALEATORIZADO OMNICARB  \n \nLanga KM, Levine DA.  The diagnosis and management of mild cognitive impairment: a clinical review. JAMA \n2014;312:2551 -2561 [R,I]  \n25514304  R/C \nDIAGN\u00d3STICO Y MANEJO DEL DETERIORO COGNITIVO LEVE: REVISI\u00d3N CL\u00cdNICA  \n \nJAMA INTERNAL MEDICINE  \n \nMcDonagh J. Statin -related cognitive impairment in the real world: you'll live longer, but you might not like it. JAMA Intern \nMed 2014;174:1889 [AO,I]  \n25347692   \nDETERIORO COGNITIVO RELACIONADO CON LAS ESTATINAS EN EL MUNDO REAL: VIVIR\u00c1S M\u00c1S, PERO \nPUEDE QUE NO TE GUSTE  \n \nGarin N, Genn\u00e9 D, Carballo S, Chuard C, Eich G, Hugli O, et al. \u00df -Lactam monotherapy vs \u00df -Lactam -macrol ide \ncombination treatment in moderately severe community -acquired pneumonia: a randomized noninferiority trial. JAMA \nIntern Med 2014;174:1894 -1901 [EC,I]  \n25286173  R/C MONOTERAPIA CON BETA -LACT\u00c1MICOS FRENTE A TRATAMIENTO COMBINADO BETA -LACT\u00c1MICOS Y \nMACR\u00d3LIDOS EN LA NEUMON\u00cdA ADQUIRIDA EN LA COMUNIDAD MODERADAMENTE GRAVE: ENSAYO DE NO \nINFERIORIDAD ALEATORIZADO  \n \nRostron BL, Chang CM, Pechacek TF. Estimation of cigarette smo king-attributable morbidity in the United States. JAMA \nIntern Med 2014;174:1922 -1928 [T,II]  \n25317719  R/C \nC\u00c1LCULO DE LA MORBILIDAD ATRIBUIBLE A CONSUMO DE CIGARRILLOS E N EE UU  \n \nMoore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping \nassociated with dopamine receptor agonist drugs. JAMA Intern Med 2014;174:1930 -1933 [T,II]  \n25329919  R/C \nINFORMES DE JUEGO PATOL\u00d3GICO, HIPERSEXUALIDAD Y COMPRAS COMPULSIVAS ASOCIADOS A \nF\u00c1RMACOS AGONISTAS DE RECEPTORES DE DOPAMINA  \n \nCook NR, Ridker PM. Further insight into the cardiovascular risk calculat or: the roles of statins, revascularizations, and \nunderascertainment in the Women's Health Study. JAMA Intern Med 2014;174:1964 -1971 [S,II]  \n25285455  R/C \nREFLEXI\u00d3N POST ERIOR SOBRE LA CALCULADORA DE RIESGO CARDIOVASCULAR: PAPELES DE LAS \nESTATINAS, REVASCULARIZACIONES E INFRAESTIMACI\u00d3N EN EL ESTUDIO WOMEN'S HEALTH  \n \nBrett AS, Levine JD. The case against identifying carotid stenosis in asymptomatic patients. JAMA Intern Med \n2014;174:2004 -2008 [R,I]  \n25265407  R/C \nEL CASO CONTRA LA IDENTIFICACI\u00d3N DE ESTENOSIS CAROT\u00cdDEA EN PACIENTES ASINTOM\u00c1TICOS  \n \nWoolf SH, Harris RP, Campos -Outcalt D. Low -dose computed tomography screening for lung cancer: how strong is the \nevidence? JAMA Intern Med 2014;174:2019 -2022 [AO,II]  \n25317533  R/C \nCRIBAJE CON TC DE BAJA DOSISI PAR A EL C\u00c1NCER DE PULM\u00d3N: \u00bfCU\u00c1N FUERTE ES LA EVIDENCIA?  \n \nJAMA PSYCHIATRY  \n \nBryant RA, Kenny L, Joscelyne A, Rawson N, Maccallum F, Cahill C, et al. Treating prolonged grief disorder: a \nrandomized clinical trial. JAMA Psychiatry 20 14;71:1332 -1339 [EC,I]  \n25338187  R/C \nTRATAR EL DUELO PROLONGADO: ENSAYO CL\u00cdNICO ALEATORIZADO  \n \nPinto SM, Geoffroy MC, Power C. Depressive symptoms and physical activity during 3 decades in adult life: bidirectional \nassociations in a prospective cohort study. JAMA Psychiatry 2014;71:1373 -1380  \n[S,I] \n25321867  R/C \nS\u00cdNTOMAS DEPRESIVOS Y A CTIVIDAD F\u00cdSICA DURANTE 3 D\u00c9CADAS EN LA VIDA ADULTA: ASOCIACIONES \nBIDIRECCIONALES EN UN ESTUDIO DE COHORTE PROSPECTIVO  \n \nK\u00f6hler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti -inflammatory treatment on \ndepression, depressiv e symptoms, and adverse effects: a systematic review and meta -analysis of randomized clinical \ntrials. JAMA Psychiatry 2014;71:1381 -1391 [M,II]  \n25322082  R/C \nEFECTO DEL TRATAMIENTO ANTIINFLAMATORIO SOBRE LA DEPRESI\u00d3N, LOS S\u00cdNTOMAS DEPRESIVOS Y \nEFECTOS ADVERSOS: REVISI\u00d3N SISTEM\u00c1TICA Y METAAN\u00c1LISIS DE ENSAYOS CL\u00cdNICOS ALEATORIZADOS  \n \nMEDICINA CLINICA  \n \nPosso M, Brugulat -Guiteras P, Puig T, Mompart -Penin a A, Medina -Bustos A, Alca\u00f1iz M, et al. Prevalencia y \ncondicionantes de la obesidad en la poblaci\u00f3n infantojuvenil de Catalu\u00f1a, 2006 -2012. Med Clin (Barc) 2014;143:475 -483 \n[T,I] \n24661534  R/C \nPREVALENCIA Y CONDICIONANTES DE LA OBESIDAD EN LA POBLACI\u00d3N INFANTOJUVENIL DE CATALU\u00d1A, \n2006 -2012  \n \nRipoll\u00e9s -de Ram\u00f3n J, Mu\u00f1oz -Corcuera M, Bravo -Llatas C, Bascones -Mart\u00ednez A. Aplicaci\u00f3n de un gel de \u00e1cido \ntranex\u00e1mico en pacientes tr atados con anticoagulantes orales. Med Clin (Barc) 2014;143:484 -488 [T,I]  \n24268907  R/C \nAPLICACI\u00d3N DE UN GEL DE \u00c1CIDO TRANEX\u00c1MICO EN PACIENTES TRATADOS CON ANTICOAGULAN TES \nORALES  \n \nSerra -Majem L. Obesidad infantil: \u00bfhemos tocado fondo? \u00bfPodemos echar las campanas al vuelo? Med Clin (Barc) \n2014;143:489 -491 [AO,I]  \n24667110  OBESIDAD INFANTIL: \u00bfHEMOS TOCADO FONDO? \u00bfP ODEMOS ECHAR LAS CAMPANAS AL VUELO?  \n \nTello -Montoliu A, Jover E, Vald\u00e9s M. Nuevos antiagregantes plaquetarios en cardiopat\u00eda isqu\u00e9mica. Med Clin (Barc) \n2014;143:508 -514 [R,I]  \n24480290  R/C \nNUEVOS ANTIAGREGANTES PLAQUETARIOS EN CARDIOPAT\u00cdA ISQU\u00c9MICA  \n \nCalero -Paniagua I, Ru\u00edz -Chicote AM, Nieto -Rodr\u00edguez JA, Ruiz -Rib\u00f3 MD, Cort\u00e9s AB. Utilidad de la cistatina C como \nmarcador pron\u00f3stico en la enfermedad tromboemb\u00f3lica venosa. Me d Clin (Barc) 2014;143:530 -534 [S,I]  \n24216017  R/C \nUTILIDAD DE LA CISTATINA C COMO MARCADOR PRON\u00d3STICO EN LA ENFERMEDAD TROMBOEMB\u00d3LICA \nVENOSA  \n \nRuiz-Salas A, Cort\u00e9s -Rodr \u00edguez M, Alegre -Bayo N, Algarra -Garc\u00eda J, de Teresa E, Jim\u00e9nez -Navarro MF. Relaci\u00f3n entre \ncistatina C y calcificaci\u00f3n coronaria en pacientes con riesgo cardiovascular intermedio. Med Clin (Barc) 2014;143:535 -\n538 [T,I]  \n24725853  R/C \nRELACI\u00d3N ENTRE CISTATINA C Y CALCIFICACI\u00d3N CORONARIA EN PACIENTES CON RIESGO \nCARDIOVASCULAR INTERMEDIO  \n \nMi\u00f1ambres I, de Leiva A, P\u00e9rez A. Hipovitaminosis D y s\u00edndrome metab\u00f3lico. Med Clin (Bar c) 2014;143:542 -547 [R,I]  \n24529881  R/C \nHIPOVITAMINOSIS D Y S\u00cdNDROME METAB\u00d3LICO  \n \nMart\u00edn -Arribas MC, Mart\u00ednez -Herv\u00e1s I, Rodr\u00edguez -Lozano I, Arias -D\u00edaz J. Percepci\u00f3n del fraude cient\u00edfico en las revistas \nbiom\u00e9dicas espa\u00f1olas. Med Clin (Barc) 2014;143:554 -559 [R,I]  \n25073824  \nPERCEPCI\u00d3N DEL FRAUDE CIENT\u00cdFICO EN LAS REVISTAS BIOM\u00c9DICAS ESPA\u00d1OLAS  \n \nSCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE  \n \nLiira H, Engberg E, Lepp\u00e4vuori J, From S, Kautiainen H, Liira J, et al. Exercise intervention and health checks for middle -\naged men with elevated cardiovascular risk: a randomized controlled trial. Scan d J Prim Health Care 2014;32:156 -162 \n[EC,I]  \n25434409  R/C \nINTERVENCI\u00d3N CON EJERCICIO Y PRUEBAS DE SALUD EN HOMBRES DE MEDIANA EDAD CON RIESGO \nCARDIOVASCULAR ELEVADO: EN SAYO CONTROLADO ALEATORIZADO  \n \nAakhus E, Oxman AD, Flottorp SA. Determinants of adherence to recommendations for depressed elderly patients in \nprimary care: a multi -methods study. Scand J Prim Health Care 2014;32:170 -179 [C,T,I]  \n25431340  R/C \nDETERMINA NTES DE CUMPLIMIENTO DE LAS RECOMENDACIONES PARA PACIENTES ANCIANOS \nDEPRIMIDOS EN ATENCI\u00d3N PRIMARIA: ESTUDIO PLURIMETODOL\u00d3GICO  \n \nLenander C, Elfsson B, Danielsson B, Midl\u00f6v P , Hasselstr\u00f6m J. Effects of a pharmacist -led structured medication review \nin primary care on drug -related problems and hospital admission rates: a randomized controlled trial. Scand J Prim \nHealth Care 2014;32:180 -186 [EC,I]  \n25347723  R/C \nEFECTOS DE UNA REVISI\u00d3N ESTRUCTURADA DE LA MEDICACI\u00d3N POR PARTE DEL FARMAC\u00c9UTICO EN \nATENCI\u00d3N PRIMARIA SOBRE LOS PROBLEMAS EN RELACI\u00d3N CON LOS F\u00c1RMACOS Y SOBRE LAS TASAS DE \nINGRESO EN HOS PITAL: ENSAYO CONTROLADO ALEATORIZADO  \n \nJansen K, Schaufel MA, Ruths S. Drug treatment at the end of life: an epidemiologic study in nursing homes. Scand J \nPrim Health Care 2014;32:187 -192 [S,I]  \n25363144  R/C \nTRATAMIENTO FARMACOL\u00d3GICO  TERMINAL: ESTUDIO EPIDEMIOL\u00d3GICO EN RESIDENCIAS  \n \nHedin K, Strandberg EL, Gr\u00f6ndal H, Brorsson A, Thulesius H, Andr\u00e9 M. Management of patients with sore throats in \nrelation to guidelines: an interview study in Sweden. Scand J Prim Health Care 2014;32:193 -199 [C,I]  \n25363143  R/C \nMANEJO DE LOS PACIENTES CON DOLORES DE GARGANTA EN RELACI\u00d3N CON LAS GU\u00cdAS: ESTUDI O \nMEDIANTE ENTREVISTAS EN SUECIA  \n \nHuibers L, Moth G, Christensen MB, Vedsted P. Antibiotic prescribing patterns in out -of-hours primary care: a population -\nbased descriptive study. Scand J Prim Health Care 2014;32:200 -207 [T,I]  \n25350313  R/C \nPAUTAS DE PRESCRIPCI\u00d3N DE ANTIBI\u00d3TICOS EN ATENCI\u00d3N CONTINUADA EN ATENCI\u00d3N PRIMARIA: \nESTUDIO DESCRIPTIVO POBLACIONAL  \n Johansson C, H\u00e4gg L, Johansson L, Jansson JH. Characterization of patients with atrial fibrillation not treated with oral \nanticoagulants. Scand J Prim Health Care 2014;32:226 -231 [T,I]  \n25464863  R/C \nCARACTERIZACI\u00d3N DE LOS PACIENTES CO N FIBRILACI\u00d3N AURICULAR NO TRATADOS CON \nANTICOAGULANTES ORALES  \n \nDiaz E, Gimeno -Feliu LA, Calder\u00f3n -Larra\u00f1aga A, Prados -Torres A. Frequent attenders in general practice and immigrant \nstatus in Norway: a nationwide cross -sectional study. Scand J Prim Health C are 2014;32:232 -240 [T,I]  \n25421090  R/C \nHIPERFRECUENTADORES EN MEDICINA GENERAL Y CONDICI\u00d3N DE INMIGRANTE EN NORUEGA: ESTUDIO \nTRANSVERSAL NACIONAL  \n \nNilsson S, Andersson  A, Janzon M, Karlsson JE, Levin L\u00c5. Cost consequences of point -of-care troponin T testing in a \nSwedish primary health care setting. Scand J Prim Health Care 2014;32:241 -247 [S,I]  \n25434410  R/C \nCON SECUENCIAS DE COSTE DE LA PRUEBA R\u00c1PIDA DE TROPONINA T EN UN DISPOSITIVO DE  ATENCI\u00d3N \nPRMARIA DE SALUD SUECO  \n \nTHE LANCET  \n \nHill MD, Coutts SB. Alteplase in acute ischaemic stroke: the need for speed. Lancet 2014;384:1904 -1906 [AO,I]  \n25106064   \nALTEPLASA EN EL ICTUS ISQU\u00c9MICO AGUDO: NECESIDAD DE VELOCIDAD  \n \nChiasson JL, Le Lorier J. Glycaemic control, cardiovascular disease, and mortality in type 2  diabetes. Lancet \n2014;384:1906 -1907 [AO,I]  \n25088436   \nCONTROL GLUC\u00c9MICO, ENFERMEDAD CARDIOVASCULAR Y MORTALIDAD EN LA DIABETES TIPO 2  \n \nWilliams R, Aspinall R, Bellis M, Camps -Walsh G, Cramp M, Dha wan A, et al. Addressing liver disease in the UK: a \nblueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess \nconsumption of alcohol, obesity, and viral hepatitis. Lancet 2014;384:1953 -1997 [M,II]  \n25513438   \nABORDAJE DE LA ENFERMEDAD HEP\u00c1TICA EN R.U.: PLAN DE ACCI\u00d3N PARA ALCANZAR LA EXCELENCIA EN \nLA ATENCI\u00d3N SANITARIA Y REDUCIR LA MORTALIDAD PREMATURA A PARTIR DE CUESTIONES DE H\u00c1BITOS \nCOMO EL CONSUMO EXCESIVO DE ALCOHOL, OBESIDAD HEPATITITS V\u00cdRICA  \n \nRoberts I, Perner A. Ebola virus disease: clinical care and patient -centred research. Lancet 2014;384:2001 -2002 [AO,I]  \n25483156   \nENFERMEDAD  POR EL VIRUS DEL \u00c9BOLA: ATENCI\u00d3N CL\u00cdNICA E INVESTIGACI\u00d3N ENFOCADA AL PACIENTE  \n \nSchr\u00f6der FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al; ERSPC Investigators. Screening and \nprostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 \nyears of follow -up. Lancet 2014;384:2027 -2035 [EC,II]  \n25108889  R/C \nCRIBAJE Y MORTALIDAD POR C\u00c1NCER DE PR\u00d3STATA: RESULTAD OS DEL ESTUDIO ERSPC TRAS 13 A\u00d1OS DE \nSEGUIMIENTO  \n \nDrug labelling and pregnancy. Lancet 2014;384:2084 [AO,I]  \n25497185   \nETIQUETADO DE MEDICAMENTOS Y EMBARAZO  \n \nTHE NEW ENGLAND  JOURNAL OF MEDICINE  \n \nColombo A, Chieffo A. Dual antiplatelet therapy after drug -eluting stents --how long to treat? N Engl J Med \n2014;371:2225 -2226 [AO,I]  \n25399657   \nTERAPIA ANTIPLAQUETARIA DOBLE TRAS STENTS FARMACOACTIVOS \u00bfDURANTE CU\u00c1NTO TRATAR?  \n \nKanapathipillai R, Henao AM, Fast P, Wood D, Dye C, Kieny MP, et al. Ebola vaccine --an urgent international priority. N \nEngl J Med 2014;371:2249 -2251  \n[AO,I]  \n25289888   \nVACUNA CONTRA EL \u00c9BOLA --PRIORIDAD INTERNACIONAL URGENTE  \n \nChin MH. How to achieve health equity. N Engl J Med 2014;371:2331 -2332 [AO,I]  \n25494273   \nC\u00d3MO CONSEGUIR LA EQUIDAD S ANITARIA  \n Gonsalves G, Staley P. Panic, paranoia, and public health --the AIDS epidemic's lessons for Ebola. N Engl J Med \n2014;371:2348 -2349 [AO,I]  \n25372947  \nP\u00c1NICO, PARANOIA Y SALUD P\u00daBLICA --LECCIO NES EPID\u00c9MICAS DEL SIDA PARA EL \u00c9BOLA  \n \nWalker N, Howe C, Glover M, McRobbie H, Barnes J, Nosa V, et al. Cytisine versus nicotine for smoking cessation. N \nEngl J Med 2014;371:2353 -2362 [EC,I]  \n255177 06 R/C \nCITISINA FRENTE A NICOTINA PARA EL ABANDONO TAB\u00c1QUICO  \n \nRigotti NA. Cytisine --a tobacco treatment hiding in plain sight. N Engl J Med 2014;371:2429 -2430 [AO,I]  \n25517710   \nCITISINA -- TRATAMIENTO PARA EL TABACO ESCONDIDO A SIMPLE VISTA  \n \nTHORAX  \n \nP\u00e9pin JL, Timsit JF, Tamisier R, L\u00e9vy P. Is CPAP effective in reducing blood pressure in minimally symptomatic \nobstructive sleep apnoea? Thorax 201 4;69:1068 -1070 [AO,I]  \n25084789  \n\u00bfES EFECTIVO EL CPAP PARA REDUCIR LA PRESI\u00d3N ARTERIAL EN LA APNEA OBSTRUCTIVA DEL SUE\u00d1O \nM\u00cdNIMAMENTE SINTOM\u00c1TICA?  \n \nHalpin DM, Quint JK. The WISDOM of inhaled corticos teroids in COPD. Thorax 2014;69:1071 -1072 [AO,I]  \n25323619  \nLA SABIDUR\u00cdA (WISDOM, por el estudio WISDOM) DE LOS CORTICOIDES INHALADOS EN LA EPOC  \n \nBratton DJ, Stradling JR, Barb\u00e9 F, Kohler M. Effect  of CPAP on blood pressure in patients with minimally symptomatic \nobstructive sleep apnoea: a meta -analysis using individual patient data from four randomised controlled trials. Thorax \n2014;69:1128 -1135 [M,II]  \n24947425  R/C \nEFECTO DEL CPAP SOBRE LA PRESI\u00d3N ARTERIAL EN PACIENTES CON APNEA OBSTRUCTIVA DEL SUE\u00d1O \nM\u00cdNIMAMENTE SINTOM\u00c1TICA: METAAN\u00c1LISIS USANDO DATOS INDIVIDUALES DE PACIENTES DE CUATRO \nENSAYOS CONTROLADOS ALEATO RIZADOS  \n \n \nANNALS OF INTERNAL MEDICINE  \n \nS25244227  \nThe USPSTF recommends intensive behavioral counseling for all sexually active adolescents and for adults who are at increased  risk \nfor STIs. (B recommendation).  \nS25200125  \nThe USPSTF recommends the use of l ow-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who \nare at high risk for preeclampsia. (B recommendation).  \nS25243785  \nThe USPSTF recommends screening for chlamydia in sexually active females aged 24 years or younger and in older women who are at \nincreased risk for infection. (B recommendation) The USPSTF recommends screening for gonorrhea in sexually active females age d 24 \nyears or younger and in older women who are at increased risk for infection. (B recommendation) The USPSTF concludes that the \ncurrent evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men.  (I \nstatement).  \nS25244000  \nChlamydia screening in young women may reduce the incidence of pelvic infl ammatory disease. Nucleic acid amplification tests are \naccurate for diagnosing gonorrhea and chlamydia in asymptomatic persons.  \n \nARCHIVOS DE BRONCONEUMOLOGIA  \n \nS25443591  \nNuestros datos confirman diferencias cl\u00ednicas y anal\u00edticas entre una AEPOC y una NEPOC en los pacientes que precisan ingreso \nhospitalario, aunque sin diferencias en la evoluci\u00f3n posterior.  \nS25059585  \nEl s\u00edndrome de apnea -hipopnea del sue\u00f1o es una enfermedad muy prevalente, con tasas altas de infradiagn\u00f3stico en el momento \nactual, que conlleva  un elevado impacto sanitario, econ\u00f3mico y social, y consume gran parte de los recursos destinados a las terapias \nrespiratorias domiciliarias. Con motivo del A\u00f1o SEPAR 2014 del paciente cr\u00f3nico y las terapias respiratorias domiciliarias, p atrocinado \npor la  Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica, en este art\u00edculo se revisa la literatura m\u00e1s reciente publicada sobre las  \nindicaciones del tratamiento de la apnea del sue\u00f1o y sus controversias, las \u00faltimas evidencias de las indicaciones de los dis tintos \ndispositivos de presi\u00f3n positiva, as\u00ed como los modos de ajuste, desde el uso de f\u00f3rmulas emp\u00edricas o estimaciones matem\u00e1ticas , a los \nmodernos equipos de auto -CPAP, pasando por la titulaci\u00f3n manual como \u00abgold standard\u00bb. Adem\u00e1s, se hace hincapi\u00e9 en la nec esidad \nde seguimiento que los pacientes precisan para asegurar la adherencia y cumplimiento de la terapia. Por \u00faltimo, se comentan \nsomeramente otros tratamientos, que no son el objetivo del art\u00edculo.  \n \nARTHRITIS AND RHEUMATOLOGY  \n \nS25185757  Increased fat ma ss and fat:muscle mass ratio were significantly associated with musculoskeletal pain among women. Widespread pain \nwas significantly associated with a high fat:muscle mass ratio after adjustment for confounders. Understanding the relationsh ip between \nfat ma ss and pain may provide insights into preventative measures and therapeutic strategies for musculoskeletal pain.  \n \nATENCION PRIMARIA  \n \nCATALA -LOPEZ  \nLas revisiones sistem\u00e1ticas y los metaan\u00e1lisis se han consolidado como una herramienta fundamental para la pr\u00e1 ctica cl\u00ednica basada \nen la evidencia. Inicialmente, el metaan\u00e1lisis fue propuesto como una t\u00e9cnica que podr\u00eda mejorar la precisi\u00f3n y la potencia e stad\u00edstica \nde la investigaci\u00f3n procedente de estudios individuales con peque\u00f1o tama\u00f1o muestral. Sin embargo, u no de sus principales \ninconvenientes es que suelen comparar no m\u00e1s de 2 intervenciones alternativas a la vez. Los \u00abmetaan\u00e1lisis en red\u00bb utilizan t\u00e9 cnicas \nnovedosas de an\u00e1lisis que permiten incorporar la informaci\u00f3n procedente de comparaciones directas e in directas a partir de una red de \nestudios que examina los efectos de diversos tratamientos de una manera m\u00e1s completa. Pese a sus potenciales limitaciones, su  \naplicaci\u00f3n en epidemiolog\u00eda cl\u00ednica podr\u00eda ser potencialmente \u00fatil en situaciones en las que exist en varios tratamientos que se han \ncomparado frente a un comparador com\u00fan.  \nAdem\u00e1s, estas t\u00e9cnicas pueden ser relevantes ante una pregunta cl\u00ednica o de investigaci\u00f3n cuando existen m\u00faltiples tratamient os que \ndeben ser considerados, o cuando se dispone tanto de informaci\u00f3n directa como indirecta en el cuerpo de la evidencia.  \nS24863857  \nLa prevalencia de inactividad f\u00edsica descendi\u00f3 entre 1987 y 2007, y los mayores descensos fueron en sujetos con estudios \nuniversitarios. La brecha de las diferencias en prevalenc ias y OR de inactividad f\u00edsica en tiempo libre, ha aumentado con el tiempo. \nParece necesario contribuir, desde estrategias de Educaci\u00f3n para la Salud y promoci\u00f3n de la equidad, a la reducci\u00f3n de las \ndesigualdades en conductas de riesgo.  \nS24986634  \n Implemen tar una intervenci\u00f3n educativa breve en AP mejora la calidad del sue\u00f1o y potencia una menor prescripci\u00f3n de \nbenzodiacepinas.  \nS24811538  \nEn las publicaciones de atenci\u00f3n primaria existe gran diversidad tanto en \u00e1reas de investigaci\u00f3n como en las revistas don de se \npublican. La mayor\u00eda proceden de centros de salud, tratan aspectos cl\u00ednicos y se publican en revistas espa\u00f1olas. Se observan \ndiferencias en el volumen de producci\u00f3n cient\u00edfica entre comunidades aut\u00f3nomas.  \n \nBRITISH JOURNAL OF PSYCHIATRY  \n \nS25452601  \nBackground Agitation in dementia is common, persistent and distressing and can lead to care breakdown. Medication is often ineff ective \nand harmful. Aims To systematically review randomised controlled trial evidence regarding non -pharmacological interventions.  Method \nWe reviewed 33 studies fitting predetermined criteria, assessed their validity and calculated standardised effect sizes (SES) . Results \nPerson -centred care, communication skills training and adapted dementia care mapping decreased symptomatic and se vere agitation in \ncare homes immediately (SES range 0.3 -1.8) and for up to 6 months afterwards (SES range 0.2 -2.2). Activities and music therapy by \nprotocol (SES range 0.5 -0.6) decreased overall agitation and sensory intervention decreased clinically signi ficant agitation immediately. \nAromatherapy and light therapy did not demonstrate efficacy. Conclusions There are evidence -based strategies for care homes. Future \ninterventions should focus on consistent and long -term implementation through staff training. Further research is needed for people \nliving in their own homes.  \nS25452599  \nWork -related mental health disorders are a major public health problem. Consequently, psychiatrists encounter many patients whose \nclinical state is profoundly affected by work condi tions. Psychiatrists therefore, need training in occupational/stress medicine. This would \nhelp integrate health services for these patients, aimed at preservation of work fitness and mental health.  \nS25359926  \nOverall, this study confirms a general relations hip between the economic environment and suicide rates; however, it does not support \nthere being a clear causal relationship between the current economic crisis and an increase in the suicide rate.  \n \nBRITISH MEDICAL JOURNAL  \n \nS25225003  \nUrinary incontinence affects women of all ages. History, physical examination, and certain tests can guide specialists in diagnosing \nstress urinary incontinence, urgency urinary incontinence, and mixed urinary incontinence. First line management includes lif estyle and \nbehavior  modification, as well as pelvic floor strength and bladder training. Drug therapy is helpful in the treatment of urgency \nincontinence that does not respond to conservative measures. In addition, sacral neuromodulation, intravesical onabotulinumto xinA \ninjections, and posterior tibial nerve stimulation can be used in select patient populations with drug refractory urgency inconti nence. \nMidurethral synthetic slings, including retropubic and transobturator approaches, are safe and efficacious surgical options for stress \nurinary incontinence and have replaced more invasive bladder neck slings that use autologous or cadaveric fascia. Despite con troversy \nsurrounding vaginal mesh for prolapse, synthetic slings for the treatment of stress urinary incontinence are co nsidered safe and \nminimally invasive.  \nS25500116  \nGeneral practice waiting rooms contain mainly old magazines. This phenomenon relates to the disappearance of the magazines ra ther \nthan to the supply of old ones. Gossipy magazines were more likely to disappe ar than non -gossipy ones. On the grounds of cost we \nadvise practices to supply old copies of non -gossipy magazines. A waiting room science curriculum is urgently needed.  \nS25398372  \nAngiotensin receptor blocker showed beneficial effects comparable with ACE inhibitors in patients with ST segment elevation \nmyocardial infarction with preserved left ventricular systolic function. Angiotensin receptor blockers could be used as an al ternative to \nACE inhibitors in such patients.  \nS25498121  \nExaggeration in news is st rongly associated with exaggeration in press releases. Improving the accuracy of academic press releases \ncould represent a key opportunity for reducing misleading health related news.  \n \nCANADIAN MEDICAL ASSOCIATION JOURNAL  \n \nS25349008  We found no significan t difference in analgesic efficacy between orally administered morphine and ibuprofen. However, morphine was \nassociated with a significantly greater number of adverse effects. Our results suggest that ibuprofen remains safe and effect ive for \noutpatient pai n management in children with uncomplicated fractures.  \n \nCIRCULATION  \n \nS25378546  \n-The current study indicated a U -shaped association of BMI with all -cause mortality risk among African American and white patients with \ntype 2 diabetes. A significantly increase d risk of all -cause mortality was observed among African Americans with BMI<30 kg/m2 and \nBMI =35 kg/m2, and among whites with BMI<25 kg/m2 and BMI =40 kg/m2 compared with patients with BMI 30 -34.9 kg/m2.  \nS25378545  \nDespite the persistence of the obesity epi demic and its contribution to development of metabolic and cardiovascular diseases, a growing \nnumber of studies have described a paradoxically longer survival (the \"obesity paradox\") among overweight and obese adults wi th and \nwithout chronic diseases.1 Whe reas the obesity paradox has previously been observed among adults with chronic kidney disease, heart \nfailure and cancer, a growing number of studies have investigated this question in the setting of diabetes. Whether the obesi ty paradox \nis present in diab etes is of particular interest given the importance of obesity in the etiology of diabetes and the development of \ncomplications. In this week's issue of Circulation, Zhao and colleagues2 report a U -shaped association between weight status and \nmortality amo ng adults with diabetes whereby the lowest mortality rates are observed among adults who are overweight or obese. \nThese findings are consistent with some,3,4 but not all,5 prior findings.  \n \nDIABETES CARE  \n \nS25414390  \nA low GI diet was associated with less fre quent insulin use and lower birth weight than control diets, suggesting that it is the most \nappropriate dietary intervention to be prescribed to patients with GDM.  \nS25249651  \nLiraglutide provides robust enhancement of \u00df -cell function that is sustained over 48 weeks in early T2DM but lost upon cessation of \ntherapy.  \nS25193531  \nGla-300 was as effective as Gla -100 and associated with a lower risk of hypoglycemia during the night and at any time of the day.  \nS25336749  \nFormer and current smoking was associated with a higher risk of incident type 2 diabetes compared with never smoking in men and \nwomen, independent of educational level, physical activity, alcohol consumption, and diet. Smoking may be regarded as a modif iable \nrisk factor for type 2 diabetes, and smoking  cessation should be encouraged for diabetes prevention.  \nS25414388  \nThese statistics underscore the importance of finding ways to reduce the burden of prediabetes and diabetes through preventio n and \ntreatment.  \nS25249652  \nPHEN/TPM ER plus lifestyle modificati on can effectively promote weight loss and improve glycemic control as a treatment approach in \nobese/overweight patients with type 2 diabetes.  \n \nDRUGS  \n \nS25389049  \nDapagliflozin (Forxiga(\u00ae), Farxiga(\u00ae)) is an orally administered sodium -glucose co -transporter -2 (SGLT2) inhibitor used in the \nmanagement of patients with type 2 diabetes. Dapagliflozin reduces renal glucose reabsorption by inhibiting the transporter p rotein \nSGLT2 in the renal proximal tubule, thereby increasing urinary glucose excretion and reduci ng blood glucose levels. Its mechanism of \naction is independent of insulin secretion or action; therefore, dapagliflozin provides complementary therapy when used in co mbination \nwith other antihyperglycaemic drugs. This article updates an earlier review of dapagliflozin and focuses on longer -term efficacy and \ntolerability data (e.g. from extensions of earlier clinical trials), as well as data from studies in special patient populati ons (e.g. history of \ncardiovascular disease). Numerous well -designed clinical  trials with dapagliflozin, primarily as add -on therapy for 24 weeks (but also as \nmonotherapy or initial combination therapy), have consistently demonstrated reductions in glycosylated haemoglobin, fasting p lasma \nglucose levels and bodyweight. Extensions o f these trials show the effects are maintained over longer -term follow -up periods of \u02dc1 -4 \nyears and dapagliflozin is generally well tolerated. Dapagliflozin has a low risk of hypoglycaemia, although the incidence va ries \ndepending on background therapy, and  genital mycotic infections (particularly in women) are the most common adverse events. \nDapagliflozin is not recommended in patients with moderate or severe renal impairment. In view of its unique mechanism of act ion and \nnow well -established efficacy and t olerability profile, dapagliflozin is a useful treatment option in the management of type 2 diabetes, \nalthough its effects on diabetic complications remain to be evaluated.  \nS25414121  \nMost patients with diabetes mellitus require multiple medications to ach ieve glycemic goals. Considering this and the increasing \nincidence of type 2 diabetes worldwide, the need for effective combination therapy is pressing. Basal insulin and glucagon -like peptide 1 \n(GLP -1) receptor agonists are frequently used to treat type 2  diabetes. Though both classes of medication are exclusively injectable, \nwhich may cause initial hesitation from providers, evidence for their combined use is substantial. This review summarizes the  theoretical \nbenefit, supporting evidence, and implementat ion of a combined basal insulin -GLP-1 receptor agonist regimen. Basal insulin added to a \nGLP-1 receptor agonist reduces hemoglobin A1c (HbA1c) without weight gain or significantly increased hypoglycemia. A GLP -1 \nreceptor agonist added to basal insulin redu ces HbA1c and body weight. Compared with the addition of meal -time insulin to basal \ninsulin, a GLP -1 receptor agonist produces similar or greater reduction in HbA1c, weight loss instead of weight gain, and less \nhypoglycemia. Gastrointestinal adverse events  are common with GLP -1 receptor agonists, especially during initiation and titration. \nHowever, combination with basal insulin is not expected to augment expected adverse events that come with using a GLP -1 receptor \nagonist. Basal insulin can be added to a GLP-1 receptor agonist with a slow titration to target goal fasting plasma glucose. In patients \nstarting a GLP -1 receptor agonist, the dose of basal insulin should be decreased by 20 % in patients with an HbA1c =8 %. The evidence \nfrom 15 randomized prospec tive studies supports the combined use of a GLP -1 receptor agonist with basal insulin in a broad range of \npatients with uncontrolled type 2 diabetes.  \nS25367717  \nSubcutaneous liraglutide (Victoza(\u00ae)), a glucagon -like peptide 1 receptor agonist, is approved for the treatment of adult patients with \ntype 2 diabetes mellitus. Once -daily liraglutide, as monotherapy or add -on therapy to other antidiabetic agents (including basal insulin), \nwas an effective and generally well tolerated treatment in adult patients wi th type 2 diabetes in several well -designed phase III trials and \nin the real world clinical practice setting. In addition to improving glycaemic control, liraglutide had beneficial effects o n bodyweight, \nsystolic blood pressure and surrogate measures of \u00df -cell function in clinical trials, with these benefits maintained during long -term treatment (=2 years). Liraglutide has a convenient once -daily administration regimen, a low potential for drug -drug interactions and low \npropensity to cause hypoglycaemia. Th us, liraglutide continues to be a useful option for the management of type 2 diabetes. This article \nreviews the therapeutic use of liraglutide in adult patients with type 2 diabetes and summarizes its pharmacological properti es. \nS25385556  \nPramipexole, a n on-ergolinic, D3 -preferring dopamine agonist (DA), is well established as a treatment option for motor symptoms at all \nstages of Parkinson's disease (PD). It is administered orally and is available as both a three -times daily immediate -release (IR) \nformula tion and a once -daily extended -release (ER) formulation (Mirapex(\u00ae) ER, Mirapexin(\u00ae) ER; Pexola(\u00ae) ER, Sifrol(\u00ae) ER). The \ntwo formulations are bioequivalent; the majority (>80 %) of patients can be switched overnight from pramipexole IR to ER with out the \nneed for dosage adjustment. In terms of improving activities of daily living and motor function in short -term (=33 -week), double -blind \nstudies, pramipexole ER was noninferior to pramipexole IR and significantly more effective than placebo as monotherapy in patients \nwith early PD, and similar to pramipexole IR and significantly more effective than placebo as adjunctive therapy to levodopa in patients \nwith advanced PD. In long -term (80 -week) extensions of these trials, open -label treatment with pramipexole ER was associated with \nsustained symptomatic benefit. Moreover, the majority of extension participants who responded to a simple convenience questio nnaire \nexpressed a preference for once -daily over three -times daily dosing. Pramipexole ER was generally well t olerated in clinical trials; no \nnew or unexpected safety signals were identified compared with the IR formulation. Head -to-head trials are needed in order to fully \ndefine the role of pramipexole ER relative to other once -daily formulations of DAs (oral rop inirole and transdermal rotigotine). \nNonetheless, by reducing the pill burden, the ER formulation of pramipexole provides a more convenient alternative to the IR \nformulation; studies specifically testing whether this translates into improved patient compli ance and symptom control are worthwhile.  \nS25352391  \nOral rifaximin 550 mg (Refero(\u00ae); Targaxan(\u00ae); Tixteller(\u00ae); Xifaxan(\u00ae)) twice daily, either alone or more commonly with medi cines \ncontaining lactulose, is approved in several countries, including the UK,  EU and USA, for use in adults with liver disease to reduce the \nrecurrence of episodes of overt hepatic encephalopathy (HE). Rifaximin is a broad -spectrum antibacterial that acts locally in the gut to \nreduce intestinal flora, including ammonia -producing sp ecies, with hyperammonaemia considered to play a central role in the \npathogenesis of HE. In a 6 -month, multinational trial in patients with liver disease, rifaximin 550 mg twice daily (\u00b1 lactulose) was an \neffective and well tolerated treatment for reducing  the recurrence of HE episodes. At study end, rifaximin therapy significantly prolonged \nthe time to the first breakthrough HE episode compared with placebo (\u00b1 lactulose), irrespective of geographical region or bas eline \npatient and disease characteristics. Rifaximin treatment also significantly reduced HE -related hospitalizations and improved health -\nrelated quality of life compared with placebo. Furthermore, the efficacy of rifaximin with or without lactulose in reducing t he recurrence of \novert HE episodes w as maintained after up to 2.5 years of treatment, with no new safety signals arising during this period. This article \nreviews the pharmacology and therapeutic efficacy of rifaximin 550 mg twice daily in reducing the recurrence of overt HE epis odes in \nadult s with liver disease.  \nS25414119  \nThe mitogen -activated protein kinase kinases (MAPKK) MEK1 and MEK2 are integral members of the MAPK/ERK signaling pathway \nand are of interest in the development of anti -cancer therapeutics. The MAPK/ERK pathway is dysregula ted in more than 30 % of \ncancers, predominately by mutations in RAS and BRAF proteins, and MEK serves as a potential downstream target for both of the se. \nThe biology of MEK inhibition is complex, as the molecule is differentially regulated by upstream RAS or RAF. This has impacted on the \npast development of MEK inhibitors as treatments for cancer and may be exploited in more rational, molecularly selected drug \ndevelopment plans in the future. The role of MEK in cancer and the mechanism of action of MEK inhi bitors is reviewed. Furthermore, \nMEK inhibitors that are available in standard practice, as well as those most advanced in clinical development, are discussed . Finally, \nnext steps in the development of MEK inhibitors are considered.  \n \nENFERMEDADES INFECCIOS AS Y MICROBIOLOGIA CLINICA  \n \nS24813928  \nUna elevada proporci\u00f3n de tratamientos antibi\u00f3ticos son susceptibles de modificaci\u00f3n, generalmente hacia la simplificaci\u00f3n. L a \nadherencia a las recomendaciones fue elevada, aunque variable, dependiendo del centro, del tipo de recomendaci\u00f3n, del periodo del \nestudio y de que la recomendaci\u00f3n se realizara mediante un comentario verbal adem\u00e1s de escrito.  \nS25023372  \nEste art\u00edculo pretende realizar una breve revisi\u00f3n de los principales conceptos en los que se basan las medidas  de prevenci\u00f3n y control \nde la infecci\u00f3n. La antisepsia comprende el conjunto de t\u00e9cnicas destinadas a la eliminaci\u00f3n total (esterilizaci\u00f3n) o mayorit aria \n(desinfecci\u00f3n) de los g\u00e9rmenes que contaminan un medio. Ambos procedimientos deben ir precedidos de u na limpieza del medio \ndonde se vayan a aplicar.  \nLa desinfecci\u00f3n se lleva a cabo por medio de biocidas o germicidas, sustancias qu\u00edmicas antimicrobianas cuyos mecanismos de a cci\u00f3n \ny resistencia son muy similares a los de los antibi\u00f3ticos. Esta similitud est \u00e1 generando inquietud por la posibilidad de cruce de \ninformaci\u00f3n gen\u00e9tica que agrave el problema de las resistencias bacterianas. La mayor\u00eda de los biocidas pueden actuar como \nantis\u00e9pticos, aplicados sobre piel y tejidos, o desinfectantes, sobre materiales  inanimados. El espectro de acci\u00f3n de los germicidas \ndepende de las caracter\u00edsticas propias del producto y de factores externos controlables: temperatura, concentraci\u00f3n, tiempo d e \nexposici\u00f3n, etc.  \nLas t\u00e9cnicas de esterilizaci\u00f3n son fundamentalmente de car\u00e1 cter f\u00edsico, a trav\u00e9s de autoclaves que exponen el material a vapor o gas \nesterilizante. Los mayores avances est\u00e1n en las exposiciones a bajas temperaturas con tiempos m\u00e1s cortos de exposici\u00f3n, en pa ralelo \ncon los avances tecnol\u00f3gicos de instrumentaci\u00f3n co n materiales que no soportan temperaturas elevadas y con rotaciones de uso altas, \npor la presi\u00f3n asistencial.  \n \nEUROPEAN HEART JOURNAL  \n \nS24497346  \nThe prevalence of masked suboptimal BP control in patients with treated and well -controlled clinic BP is high.  Clinic BP monitoring \nalone is thus inadequate to optimize BP control because many patients have an elevated nocturnal BP. These findings suggest t hat \nABPM should become more routine to confirm BP control, especially in higher risk groups and/or those with  borderline control of clinic \nBP. \nS25265973  \nDespite evidence -based interventions, coronary heart disease (CHD) remains a leading cause of global mortality. As therapies advance, \npatient non -adherence to established treatments is well recognized. Non -adher ence is a powerful confounder of evidence -based \npractice and can affect daily patient management, resulting in inappropriate therapeutic escalation with greater costs and po tential for \nharm. Moreover, it increases risk for adverse cardiac events, including  mortality. Yet, non -adherence is complex, remains difficult to \ndefine, and provider ability to identify its presence accurately remains limited. Improved screening tools are needed to dete ct at-risk \npatients, enabling appropriate targeting of intervention s. Given the rapidly expanding global population with CHD and emerging clinical \nand cost -benefits of adherence, addressing non -adherence to prescribed therapies is a top priority.  \n FAMILY PRACTICE  \n \nS25208544  \nIn patients presenting with transient or minor n eurological symptoms, calculation of ACVR did not improve diagnostic accuracy for \nTIAMS beyond that of age and sex.  \nS25192904  \nGPs' initial focus upon tissue injury during acute care, and providing a diagnostic label, may influence patients' subsequent  alignment \nwith a biomedical perspective and contribute to consultation conflict and patients' perception of blame when discussion of ps ychosocial \ninfluences is introduced. Demonstrating the relevance of the biopsychosocial model to acute LBP may improve GPs' a lignment with \nguidelines, improve their confidence to manage these patients and ultimately improve outcomes.  \nS25208543  \nSpontaneous idiopathic facial nerve (Bell's) palsy leaves residual hemifacial weakness in 29% which is severe and disfiguring  in over \nhalf of these cases. Acute medical management remains the best way to improve outcomes. Reconstructive surgery can improve long \nterm disfigurement. However, acute and surgical options are time -dependent. As family practitioners see, on average, one case every  2 \nyears, a summary of this condition based on common clinical questions may improve acute management and guide referral for tho se \nwho need specialist input. We formulated a series of clinical questions likely to be of use to family practitioners on encoun tering this \ncondition and sought evidence from the literature to answer them. The lifetime risk is 1 in 60, and is more common in pregnan cy and \ndiabetes mellitus. Patients often present with facial pain or paraesthesia, altered taste and intolerance to lou d noise in addition to facial \ndroop. It is probably caused by ischaemic compression of the facial nerve within the meatal segment of the facial canal proba bly as a \nresult of viral inflammation. When given early, high dose corticosteroids can improve outcom es. Neither antiviral therapy nor other \nadjuvant therapies are supported by evidence. As the facial muscles remain viable re -innervation targets for up to 2 years, late referrals \nrequire more complex reconstructions. Early recognition, steroid therapy and early referral for facial reanimation (when the diagnosis is \nsecure) are important features of good management when encountering these complex cases.  \nS25214508  \nPatient -doctor gender concordance/discordance is associated with their agreement/disagreement on  advice given during the \nconsultation. Physicians need to be conscious that their own demographic characteristics and perceptions might influence the quality of \nprevention counseling delivered to their patients.  \nS25298510  \nBehavioural weight loss interventi ons in primary care yield very small reductions in body weight, which are unlikely to be clinically \nsignificant. More effective management strategies are needed for the treatment of overweight and obesity.  \nS25192902  \nVery few studies have investigated assoc iations between specific multimorbidity and multi -drug therapy, and most currently focus on \nchronic disease comorbid depression outcomes. Further research needs to identify this area as key priority for older populati ons who \nare prescribed high levels of m ultiple drug therapy.  \nS25192903  \nDiscontinuation of PPIs is feasible in a clinical setting, and a substantial number of the patients treated without a clear i ndication can \nsafely reduce or discontinue treatment. Tapering seems to be the most effective way o f doing this.  \n \nGACETA SANITARIA  \n \nS25176129  \nVarones y mujeres se enfrentan a violencia de pareja durante el noviazgo de forma diferente, y ser\u00eda necesario disponer de re cursos \npara atenderlos de manera espec\u00edfica. Incluir preguntas sobre la sensaci\u00f3n de atr apamiento podr\u00eda contribuir a detectar precozmente la \nviolencia de pareja. Formas de violencia sutiles, como la coerci\u00f3n, deber\u00edan tenerse m\u00e1s en cuenta en las campa\u00f1as de \nsensibilizaci\u00f3n.  \nS25440441  \nAunque no se ha observado una mejor\u00eda en el control gluc\u00e9 mico a lo largo del seguimiento, la transmisi\u00f3n electr\u00f3nica de la informaci\u00f3n \nha resultado viable y satisfactoria para los pacientes, en quienes se ha comprobado un mayor nivel de salud percibida.  \nS25127554  \nEn Espa\u00f1a existen diferencias en la prevalencia d e mala salud percibida por CC.AA. Aunque no var\u00eda en el periodo analizado, se \nobservan desigualdades en su evoluci\u00f3n seg\u00fan el nivel educativo y el sexo, que podr\u00edan conllevar un aumento de las desigualda des en \nmujeres seg\u00fan el nivel educativo.  \n \nJOURNAL OF THE AMERICAN MEDICAL ASSOCIATION  \n \nS25461996  \nChemoimmunotherapy is the standard first -line option approach for CLL, the most common leukemia observed in adults. Treatment is \ninitiated when the disease becomes symptomatic, and survival is high following tre atment.  \nS25402757  \nAmong asymptomatic patients with type 1 or type 2 diabetes, use of CCTA to screen for CAD did not reduce the composite rate o f all-\ncause mortality, nonfatal MI, or unstable angina requiring hospitalization at 4 years. These findings do n ot support CCTA screening in \nthis population.  \nS25514303  \nIn this 5 -week controlled feeding study, diets with low glycemic index of dietary carbohydrate, compared with high glycemic index of \ndietary carbohydrate, did not result in improvements in insulin se nsitivity, lipid levels, or systolic blood pressure. In the context of an \noverall DASH -type diet, using glycemic index to select specific foods may not improve cardiovascular risk factors or insulin resistance.  \nS25401325  \nOnce -daily, low -dose aspirin did n ot significantly reduce the risk of the composite outcome of cardiovascular death, nonfatal stroke, and \nnonfatal myocardial infarction among Japanese patients 60 years or older with atherosclerotic risk factors.  \nS25514304  \nCognitive decline and MCI have im portant implications for patients and their families and will require that primary care clinicians be \nskilled in identifying and managing this common disorder as the number of older adults increases in coming decades. Current e vidence \nsupports aerobic exer cise, mental activity, and cardiovascular risk factor control in patients with MCI.  \n \nJAMA INTERNAL MEDICINE  \n \nS25285455  Statin use, revascularization procedures, and underascertainment of events do not explain the discrepancy between observed ra tes of \nASCVD  in the WHS and those predicted by the ACC/AHA pooled cohort equations. Other explanations include changing patterns of risk \nwithin more contemporary populations.  \nS25317719  \nWe estimate that US adults have had approximately 14 million major medical conditi ons that were attributable to smoking. This figure is \ngenerally conservative owing to the existence of other diseases and medical events that were not included in these estimates.  Cigarette \nsmoking remains a leading cause of preventable disease in the Unit ed States, underscoring the need for continuing and vigorous \nsmoking -prevention efforts.  \nS25317533  \nIn 2013, the US Preventive Services Task Force (USPSTF) recommended low -dose computed tomographic (CT) screening for high -risk \ncurrent and former smokers wit h a B recommendation (indicating a level of certainty that it offered moderate to substantial net benefit). \nUnder the Affordable Care Act, the USPSTF recommendation requires commercial insurers to fully cover low -dose CT. The Centers for \nMedicare & Medicai d Services (CMS) is now considering whether to also offer coverage for Medicare beneficiaries. Although the \nNational Lung Screening Trial (NLST) demonstrated the efficacy of low -dose CT, implementation of national screening may be \npremature. The magnitude of benefit from routine screening is uncertain; estimates are based on data from a single study and \nsimulation models commissioned by the USPSTF. The potential harms -which could affect a large population -include false -positive \nresults, anxiety, radiation e xposure, diagnostic workups, and the resulting complications. It is unclear if routine screening would result in \nnet benefit or net harm. The NLST may not be generalizable to a national screening program for the Medicare age group because  73% \nof NLST parti cipants were younger than 65 years. Moreover, screening outside of trial conditions is less likely to be restricted to high -\nrisk smokers and qualified imaging centers with responsible referral protocols. Until better data are available for older adu lts who  are \nscreened in ordinary (nontrial) community settings, CMS should postpone coverage of low -dose CT screening for Medicare \nbeneficiaries.  \nS25329919  \nOur findings confirm and extend the evidence that dopamine receptor agonist drugs are associated with thes e specific impulse control \ndisorders. At present, none of the dopamine receptor agonist drugs approved by the FDA have boxed warnings as part of their \nprescribing information. Our data, and data from prior studies, show the need for more prominent warnings . \nS25265407  \nCarotid ultrasonography is performed frequently to identify carotid stenosis in patients with no history of carotid -territory cerebrovascular \nischemia. The premises of such testing are that the potential benefit of endarterectomy or stenting e xceeds the potential harm in \npatients with asymptomatic stenosis and that discovery of asymptomatic stenosis may trigger beneficial changes in lifestyle o r medical \nmanagement that otherwise would not have occurred. However, given low contemporary rates of stroke in medically managed patients \nwith asymptomatic carotid stenosis, invasive carotid procedures cannot be justified in this population. Moreover, among patie nts at \nincreased cardiovascular risk, there is no evidence that carotid imaging motivates beha vioral change or improves risk stratification \nbeyond consideration of conventional risk factors. In this focused review, we address topics that should help health care pro fessionals \nadvise patients who inquire about carotid screening and patients in whom a symptomatic carotid stenosis has already been identified. \nWe conclude that there is currently no role for carotid imaging in patients without a history of carotid -territory stroke or transient ischemic \nattack.  \nS25286173  \nWe did not find noninferiority of \u00df -lactam monotherapy in patients hospitalized for moderately severe community -acquired pneumonia. \nPatients infected with atypical pathogens or with PSI category IV pneumonia had delayed clinical stability with monotherapy.  \n \nJAMA PSYCHIATRY  \n \nS25321867  \nThe r elationship between activity and depressive symptoms was bidirectional, albeit more persistent during adult life in the direc tion \nfrom activity to depressive symptoms. Findings suggest that activity may alleviate depressive symptoms in the general populat ion and, \nin turn, depressive symptoms in early adulthood may be a barrier to activity.  \nS25322082  \nOur analysis suggests that anti -inflammatory treatment, in particular celecoxib, decreases depressive symptoms without increased risks \nof adverse effects. Howe ver, a high risk of bias and high heterogeneity made the mean estimate uncertain. This study supports a proof -\nof-concept concerning the use of anti -inflammatory treatment in depression. Identification of subgroups that could benefit from such \ntreatment mig ht be warranted.  \nS25338187  \nIncluding exposure therapy that promotes emotional processing of memories of the death is an important component to achieve o ptimal \nreductions in PGD severity. Facilitating emotional responses to the death may promote greater ch anges in appraisals about the loss, \nwhich are associated with symptom reduction. Promotion of emotional processing techniques in therapies to treat patients with  PGD is \nneeded.  \n \nMEDICINA CLINICA  \n \nS24268907  \nLa aplicaci\u00f3n del \u00e1cido tranex\u00e1mico en gel (Kin Ex ogel) en pacientes en tratamiento con anticoagulantes orales favorece el grado de \ncicatrizaci\u00f3n y la coagulaci\u00f3n en las primeras 48 -72 h.  \nS24529881  \nEl s\u00edndrome metab\u00f3lico y la hipovitaminosis D constituyen 2 trastornos con elevada prevalencia que comparten  diversos factores de \nriesgo y existen amplias evidencias epidemiol\u00f3gicas que los relacionan. Aunque los mecanismos implicados en esta asociaci\u00f3n n o \nest\u00e1n bien establecidos, se ha relacionado la hipovitaminosis D con la resistencia a la insulina, la dismin uci\u00f3n en la secreci\u00f3n de \ninsulina o la activaci\u00f3n del sistema renina -angiotensina, mecanismos implicados en la fisiopatolog\u00eda del s\u00edndrome metab\u00f3lico. Sin \nembargo, la aparente ineficacia de la suplementaci\u00f3n con vitamina D sobre los componentes del s\u00edndrom e metab\u00f3lico, as\u00ed como la \nescasa informaci\u00f3n acerca del efecto de la mejor\u00eda del control de los componentes del s\u00edndrome metab\u00f3lico sobre las concentra ciones \nde vitamina, no permiten establecer los mecanismos ni la direcci\u00f3n de la relaci\u00f3n causal entre est as 2 afecciones. En general, por la \nalta prevalencia y la asociaci\u00f3n epidemiol\u00f3gica de ambos procesos, podr\u00eda considerarse la hipovitaminosis D un componente m\u00e1s  del \ns\u00edndrome metab\u00f3lico.  \nS24480290  \nEl doble tratamiento antiagregante con \u00e1cido acetilsalic\u00edli co y clopidogrel reduce considerablemente las complicaciones tromb\u00f3ticas de \nlas fases aguda y cr\u00f3nica en la cardiopat\u00eda isqu\u00e9mica. Pese al buen cumplimiento terap\u00e9utico, un porcentaje no despreciable d e \npacientes contin\u00faa presentando episodios adversos. Po r ello, nuevos compuestos farmacol\u00f3gicamente m\u00e1s favorables est\u00e1n ya \ndisponibles cl\u00ednicamente (como es el caso de prasugrel y ticagrelor) o en fases avanzadas de su desarrollo. La presente revis i\u00f3n tiene \ncomo objetivo principal la descripci\u00f3n de los nuevos  f\u00e1rmacos antiagregantes, en especial prasugrel y ticagrelor.  S24661534  \nLa obesidad y el sobrepeso en la poblaci\u00f3n infantojuvenil catalana se han mantenido estables durante 2006 -2012, siendo de las m\u00e1s \naltas de Europa. Para afrontar este importante problem a de salud p\u00fablica, es necesario un enfoque integral e interdisciplinario que \nconsidere tanto los determinantes sociales como los estilos de vida del entorno infantil.  \nS24725853  \nLos valores de CTC podr\u00edan asociarse con el CAC y con el riesgo de enfermedad coronaria. Es necesaria la aparici\u00f3n de nuevos \nestudios para conocer la importancia de estos marcadores en la pr\u00e1ctica cl\u00ednica habitual.  \nS24216017  \nLa concentraci\u00f3n de cisC en el momento del diagn\u00f3stico de los pacientes con ETEV tiene valor pron\u00f3stico, simi lar al de creatinina \ns\u00e9rica e inferior al del NT -proBNP.  \n \nSCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE  \n \nS25464863  \nAmong patients with AF without OAC treatment a reason could be identified to withhold OAC in 75%. The underuse of OAC is esti mated \nto be 25%.  \nS25350313  \nAntibiotics were most often prescribed in clinic consultations, but, in absolute terms, many were also prescribed by telephon e. The high \nprescription proportion, particularly antibacterial eye drops for young infants, suggests room for improveme nt in rational antibiotic use.  \nS25434410  \nThe use of POCT -TnT in primary care may be cost saving but at the expense of missed cases.  \nS25431340  \nA total of 352 determinants were identified, of which 99 were prioritized. The most frequently identified factor s had to do with \ndissemination of guidelines, general practitioners' time constraints, the low prioritization of elderly patients with depress ion, and the \npatients' or relatives' wish for medication. Approximately three -quarters of the determinants were fr om three of the seven domains in the \ngeneric checklist: individual healthcare professional factors, patient factors, and incentives and resources. The survey did not provide \nuseful information due to a low response rate and a lack of responses to open -ende d questions. Implications. The list of prioritized \ndeterminants can inform the design of interventions to implement recommendations for elderly patients with depression. The im portance \nof the determinants that were identified may vary across communities, p ractices. and patients. Interventions that address important \ndeterminants are necessary to improve practice.  \nS25363144  \nPalliative drug therapy and drug therapy changes are common for nursing home patients on the last day of life. Improvements i n end -of-\nlife care in nursing homes imply addressing prognostication and earlier response to palliative needs.  \nS25347723  \nThe addition of a skilled pharmacist to the primary care team may contribute to reductions in numbers of drugs and maintenanc e of self -\nrated heal th in elderly patients with polypharmacy.  \nS25434409  \nPhysical activity increased in all study groups of middle -aged men in this health -promotion trial. The interventions had no effect on \nmetabolic syndrome or other cardiovascular outcomes in the participan ts. The trial increased awareness and collaboration in physical \nactivity promotion among municipal health care and exercise services.  \nS25421090  \nAlthough immigrants account for a small percentage of all FAs, GPs and policy -makers should be aware of differe nces in \nsocioeconomic and morbidity profiles to provide equality of health care.  \nS25363143  \nThis interview study of sore throat management in a strategically sampled group of Swedish GPs showed that while two -thirds were \nnon-adherent and had a liberal atti tude to antibiotics one -third were guideline adherent with a restricted view on antibiotics. Non -\nadherent GPs revealed significant knowledge gaps. Adherent GPs had discussed guidelines within the primary care team while no n-\nadherent GPs had not. Guideline implementation thus seemed to be promoted by knowledge shared in team discussions.  \n \nTHE LANCET  \n \nS25108889  \nIn this update the ERSPC confirms a substantial reduction in prostate cancer mortality attributable to testing of PSA, with a  substantially \nincreased  absolute effect at 13 years compared with findings after 9 and 11 years. Despite our findings, further quantification of harm s \nand their reduction are still considered a prerequisite for the introduction of populated -based screening.  \n \nTHE NEW ENGLAND JOUR NAL OF MEDICINE  \n \nS25517706  \nWhen combined with brief behavioral support, cytisine was found to be superior to nicotine -replacement therapy in helping smokers quit \nsmoking, but it was associated with a higher frequency of self -reported adverse events. (Fund ed by the Health Research Council of \nNew Zealand; Australian New Zealand Clinical Trials Registry number, ACTRN12610000590066.).  \n \nTHORAX  \n \nS24947425  \nAlthough CPAP treatment reduces OSA severity and sleepiness, it seems not to have a beneficial effect on BP in patients with \nminimally symptomatic OSA, except in patients who used CPAP for >4 h/night.  \n \n \n \n \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}